Showing 61-70 of 5643 results for "".
New Practice, Noh Problem: Lessons From Opening a Cold Start Practice
https://modernod.com/podcasts/to-the-point/new-practice-noh-problem-lessons-from-opening-a-cold-start-practice/36932/Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, welcome this month’s guest, Ada Noh, OD. Dr. Noh shares her story of how she came to open her very own practice, dedicated solely to dry eye, in a brand new city. She talks about building up her patient base, networking with local provFinally, a Treatment for Demodex Blepharitis
https://modernod.com/videos/eye-care-insiders/sl-are-you-prepared-to-treat-demodex-blepharitis-ph-heres-what-you-need-to-know-about-the-first-fda-approved-treatment-title-finally-a-treatment-for-demodex-blepharitis-the-first-fda-approved-treatment-for-idemodex-blepharitisi/37330/The first FDA-approved treatment for Demodex blepharitis has arrived, and Joseph J. Allen, OD, FAAO, Dipl ABO, reviews what you need to know to start using it in your clinic. He discusses the novel mechanism of action of lotilaner ophthalmic solution 0.25% (Xdemvy, formerly TP-03; Tarsus PharmaceutiDemodex Blepharitis Under the Microscope
https://modernod.com/videos/eye-care-insiders/eye-care-insiders-may-2023-video/37325/Joseph Allen, OD, FAAO, Dipl ABO, tackles management of Demodex blepharitis in this month’s episode of Eye Care Insiders. He reviews what causes it, how to identify the signs and symptoms, available treatments and off-label options, patient education, novel therapies in the pipeline, and more.How to Diagnose and Treat Nocturnal Lagophthalmos
https://modernod.com/podcasts/to-the-point/how-to-diagnose-and-treat-nocturnal-lagophthalmos/36914/This month, Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, dedicate the episode to the fairly common, yet sometimes elusive condition, nocturnal lagophthalmos, which clinicians encounter in their patients with dry eye. They pick the brain of Douglas K. Devries, OD, who talks about how he ideNew Drugs and Delivery Options in Glaucoma
https://modernod.com/topics/glaucoma/new-drugs-and-delivery-options-in-glaucoma/38069/Many are in development.Antioxidant Molecule Under Evaluation for Delaying Cataract Progression
https://modernod.com/articles/significant-findings/antioxidant-molecule-under-evaluation-for-delaying-cataract-progression/37743/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatTaking Stock of the Latest Developments in Myopia
https://modernod.com/topics/myopia/taking-stock-of-the-latest-developments-in-myopia/38829/A what’s what of surgical and nonsurgical treatment options, as well as new diagnostic tools and company outreach efforts.Study Shows Record Decline in US Drug Stores
https://modernod.com/articles/significant-findings/study-shows-record-decline-in-us-drug-stores/37815/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatDecoding Color Vision
https://modernod.com/articles/significant-findings/decoding-color-vision/37782/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatB+L Receives Approval in Europe for LuxLife IOL
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-receives-approval-in-europe-for-luxlife-iol/37084/Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions Learn more about your ad choices. Visit meg